Fig. 1From: Ligand-based drug design of quinazolin-4(3H)-ones as breast cancer inhibitors using QSAR modeling, molecular docking, and pharmacological profilingPlot of experimental pIC50 of the training and test sets against their predicted activitiesBack to article page